Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials

By afschroeder • August 7, 2026

Armstrong AW, Lebwohl M, Warren RB, Morita A, Paul C, Thaçi D, Augustin M, Puig L, Daamen C, Li J, Alió A, Aggrey-Amable A, Scotto J, Popmihajlov Z, Vaile J, Strober B. Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials. Am J Clin Dermatol. 2026 Aug 7. doi: 10.1007/s40257-026-01055-w. Epub ahead of print. PMID: 42563042.

Tags: Dermatology, Publications

Diagnosis and management of anti-p200 pemphigoid: Perspectives of international dermatologists with expertise in immunobullous diseases

Kasperkiewicz M, Xu J, Thapa M, Culton DA, Curman P, Hashimoto T, Meijer JM, Patsatsi A, Tomayko MM, Lehman JS, Schmidt E. Diagnosis and management[...]

Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis

Armstrong AW, Ameen A, Ferrucci S, Pereyra-Rodríguez JJ, Cork MJ, Rubin C, Jarell A, Narcisi A, Becherel PA, Beecker J, Festini T, Vittrup I, Vinther[...]

Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review

Armstrong AW, Strober BE, Liu CM, Cather JC, Merola JF, Lebwohl MG. Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a[...]